Opinion|Videos|March 20, 2025
Clinical Perspectives on Early Use of RAD-ENZ
Panelists discuss how early implementation of RAD-ENZ combination therapy requires careful consideration of patient characteristics, disease burden, and long-term treatment planning while potentially offering the greatest benefit when initiated before significant disease progression occurs.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are your clinical perspectives on using this combination therapy upfront and early in the disease stage?
- How can the findings from PEACE-3 influence the design of future trials, particularly with respect to patient selection, end points, and safety monitoring?
Advertisement
Related to this article
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
Take a look through some of the notable data presentations at this year's ESMO Congress.
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
The agency issued a PDUFA target action date of June 14, 2027.
Advertisement
Advertisement
Trending on Urology Times
1
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
2
How PSMA-PET shapes staging and recurrence workup in prostate cancer
3
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
4
ESMO 2026: Key presentations across genitourinary oncology
5